Content deleted Content added
ClueBot NG (talk | contribs) m Reverting possible vandalism by 203.153.253.102 to version by Dag330. Report False Positive? Thanks, ClueBot NG. (4306319) (Bot) |
Undid revision 1233872221 by 78.33.153.98 (talk) rv test edit |
||
(6 intermediate revisions by 6 users not shown) | |||
Line 34:
<!-- Epidemiology -->
Skin cancer is the most common form of cancer, globally accounting for at least 40% of cancer cases.<ref name=Cak2012>{{cite journal | vauthors = Cakir BÖ, Adamson P, Cingi C | title = Epidemiology and economic burden of nonmelanoma skin cancer | journal = Facial Plastic Surgery Clinics of North America | volume = 20 | issue = 4 | pages = 419–422 | date = November 2012 | pmid = 23084294 | doi = 10.1016/j.fsc.2012.07.004 }}</ref><ref>{{cite journal | vauthors = Dubas LE, Ingraffea A | title = Nonmelanoma skin cancer | journal = Facial Plastic Surgery Clinics of North America | volume = 21 | issue = 1 | pages = 43–53 | date = February 2013 | pmid = 23369588 | doi = 10.1016/j.fsc.2012.10.003 }}</ref> The most common type is nonmelanoma skin cancer, which occurs in at least 2–3 million people per year.<ref name="WCR2014" /><ref>{{cite web|title=How common is skin cancer?|url=https://www.who.int/uv/faq/skincancer/en/index1.html|website=World Health Organization|access-date=30 June 2014|url-status=live|archive-url=https://web.archive.org/web/20100927065836/http://www.who.int/uv/faq/skincancer/en/index1.html|archive-date=27 September 2010}}</ref> This is a rough estimate
{{TOC limit}}
Line 146:
Treatments for metastatic melanoma include biologic immunotherapy agents [[ipilimumab]], [[pembrolizumab]], [[nivolumab]], [[cemiplimab]]; [[BRAF inhibitor]]s, such as [[vemurafenib]] and [[dabrafenib]]; and a [[MEK inhibitor]] [[trametinib]].<ref>{{cite journal | vauthors = Maverakis E, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F | display-authors = 6 | title = Metastatic melanoma - a review of current and future treatment options | journal = Acta Dermato-Venereologica | volume = 95 | issue = 5 | pages = 516–524 | date = May 2015 | pmid = 25520039 | doi = 10.2340/00015555-2035 | doi-access = free }}</ref>
In February 2024, the Food and Drug Administration approved the first cancer treatment that uses tumor-infiltrating lymphocytes, also called TIL therapy, specifically for melanomas that have not improved with other treatments. Additionally, scientists are testing a vaccine designed to match the unique genetic details of a patient's cancer in an advanced clinical trial.<ref>{{Cite news |last=Alcorn |first=Ted |date=April 15, 2024 |title=How to Avoid One of the Deadliest Forms of Skin Cancer |url=https://www.nytimes.com/article/melanoma-skin-cancer-symptoms-risk.html |work=The New York Times}}</ref>
=== Reconstruction ===
Line 218 ⟶ 220:
{{Commons category|Skin cancers}}
* {{Curlie|Health/Conditions_and_Diseases/Cancer/Skin}}
* [http://www.oncolex.org/en/Skin-cancer Skin cancer procedures: text, images and videos] {{Webarchive|url=https://web.archive.org/web/20131207034706/http://www.oncolex.org/en/Skin-cancer |date=7 December 2013 }}
{{Tumors}}
|